Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00680758
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cisplatin, paclitaxel, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2013
Locations: Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee +3 locations
Conditions: Breast Cancer
Register for Updates
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapie... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
03/06/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
Register for Updates
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00020709
Completed
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of tumors. It is not y... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2013
Locations: Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
NCT01042041
Completed
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: This phase I trial is studying side effects and best dose... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2013
Locations: Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
Register for Updates
RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
NCT01058408
Terminated
RAD001 is approved by the U.S Food and Drug Administration (FDA) to treat advanced kidney cancer. This drug has also been used in other research studies to evaluate its effectiveness in other cancers. Information from these research studies suggests that RAD001 may help to decrease the growth and development of tumor cells by reducing the blood supply that tumors need to grow. In this research study, we are trying to determine the safety of RAD001 when given to people with locally advanced head... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Head and Neck Cancer
Register for Updates
S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
NCT00014196
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have stage IIIB non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +96 locations
Conditions: Lung Cancer
Register for Updates
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
NCT00004189
Completed
Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2013
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas +2 locations
Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00057850
Completed
Phase I/II trial to study the effectiveness of combining BMS-247550 with cisplatin in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2013
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Head and Neck Cancer
Register for Updates
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
NCT00007982
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with central nervous system cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York
Conditions: Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma
Register for Updates
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
NCT00023998
Completed
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of chemotherapy with or without trastuzumab in treating patients who have metastatic osteosarcoma
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/01/2013
Locations: Children's Oncology Group, Arcadia, California
Conditions: Metastatic Osteosarcoma
Register for Updates
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
NCT00042835
Terminated
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib and radiation therapy with combination chemotherapy may kill more tumor cells. Phase I trial to study the effectiveness of combining erlotinib and radiation therapy with combination chemotherapy in treatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2013
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
NCT00003569
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +2 locations
Conditions: Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Register for Updates